(HII) Huntington Ingalls - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4464131063
Stock: Warships, Submarines, Carriers, Nuclear Support, C5ISR
Total Rating 61
Risk 84
Buy Signal 1.70
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.32% |
| Yield on Cost 5y | 3.68% |
| Yield CAGR 5y | 4.23% |
| Payout Consistency | 100.0% |
| Payout Ratio | 35.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 49.0% |
| Relative Tail Risk | -25.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.69 |
| Alpha | 96.28 |
| Character TTM | |
|---|---|
| Beta | 0.673 |
| Beta Downside | 0.678 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.21% |
| CAGR/Max DD | 0.54 |
Description: HII Huntington Ingalls January 04, 2026
Huntington Ingalls Industries (HII) is the U.S. Navy’s primary shipbuilder, designing, constructing, overhauling, and repairing both non-nuclear (amphibious assault ships, surface combatants, Coast Guard cutters) and nuclear-powered platforms (aircraft carriers, submarines). The firm operates through three segments-Ingalls, Newport News, and Mission Technologies-and also supplies C5ISR, AI-driven decision tools, cyber-electronic warfare, and autonomous systems to support fleet sustainment.
Key quantitative drivers: (1) Backlog ≈ $41 billion at FY 2024 end, providing multi-year revenue visibility; (2) Free-cash-flow conversion ≈ 45% of operating cash, underpinning dividend sustainability; (3) U.S. defense spending outlook-annual FY 2025 defense budget projected to rise ~3% YoY, with the Navy earmarking >$15 billion for new ship construction, directly feeding HII’s order pipeline. Sensitivity to federal budget cycles and ship-yard labor constraints remains a material risk.
For a deeper dive into HII’s valuation dynamics and scenario modeling, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 605.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 6.03 > 1.0 |
| NWC/Revenue: 3.25% < 20% (prev 2.05%; Δ 1.20% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.20b > Net Income 605.0m |
| Net Debt (2.37b) to EBITDA (1.21b): 1.96 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.4m) vs 12m ago 0.77% < -2% |
| Gross Margin: 12.70% > 18% (prev 0.13%; Δ 1257 % > 0.5%) |
| Asset Turnover: 100.3% > 50% (prev 95.01%; Δ 5.30% > 0%) |
| Interest Coverage Ratio: 8.40 > 6 (EBITDA TTM 1.21b / Interest Expense TTM 105.0m) |
Altman Z'' 2.83
| A: 0.03 (Total Current Assets 3.45b - Total Current Liabilities 3.04b) / Total Assets 12.75b |
| B: 0.43 (Retained Earnings 5.49b / Total Assets 12.75b) |
| C: 0.07 (EBIT TTM 882.0m / Avg Total Assets 12.45b) |
| D: 0.71 (Book Value of Equity 5.43b / Total Liabilities 7.68b) |
| Altman-Z'' Score: 2.83 = A |
Beneish M -3.74
| DSRI: 0.15 (Receivables 339.0m/2.10b, Revenue 12.48b/11.54b) |
| GMI: 0.99 (GM 12.70% / 12.57%) |
| AQI: 0.97 (AQ_t 0.42 / AQ_t-1 0.43) |
| SGI: 1.08 (Revenue 12.48b / 11.54b) |
| TATA: -0.05 (NI 605.0m - CFO 1.20b) / TA 12.75b) |
| Beneish M-Score: -3.74 (Cap -4..+1) = AAA |
What is the price of HII shares?
As of February 09, 2026, the stock is trading at USD 397.77 with a total of 774,860 shares traded.
Over the past week, the price has changed by -5.36%, over one month by +5.10%, over three months by +25.38% and over the past year by +141.92%.
Over the past week, the price has changed by -5.36%, over one month by +5.10%, over three months by +25.38% and over the past year by +141.92%.
Is HII a buy, sell or hold?
Huntington Ingalls has received a consensus analysts rating of 3.38.
Therefor, it is recommend to hold HII.
- StrongBuy: 2
- Buy: 2
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HII price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 381.2 | -4.2% |
| Analysts Target Price | 381.2 | -4.2% |
| ValueRay Target Price | 498.1 | 25.2% |
HII Fundamental Data Overview February 07, 2026
P/E Trailing = 28.4796
P/E Forward = 22.779
P/S = 1.2067
P/B = 3.2529
P/EG = 1.2881
Revenue TTM = 12.48b USD
EBIT TTM = 882.0m USD
EBITDA TTM = 1.21b USD
Long Term Debt = 2.70b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 3.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.37b USD (from netDebt column, last quarter)
Enterprise Value = 16.87b USD (14.50b + Debt 3.15b - CCE 774.0m)
Interest Coverage Ratio = 8.40 (Ebit TTM 882.0m / Interest Expense TTM 105.0m)
EV/FCF = 15.88x (Enterprise Value 16.87b / FCF TTM 1.06b)
FCF Yield = 6.30% (FCF TTM 1.06b / Enterprise Value 16.87b)
FCF Margin = 8.51% (FCF TTM 1.06b / Revenue TTM 12.48b)
Net Margin = 4.85% (Net Income TTM 605.0m / Revenue TTM 12.48b)
Gross Margin = 12.70% ((Revenue TTM 12.48b - Cost of Revenue TTM 10.90b) / Revenue TTM)
Gross Margin QoQ = 11.57% (prev 12.34%)
Tobins Q-Ratio = 1.32 (Enterprise Value 16.87b / Total Assets 12.75b)
Interest Expense / Debt = 0.83% (Interest Expense 26.0m / Debt 3.15b)
Taxrate = 19.70% (39.0m / 198.0m)
NOPAT = 708.3m (EBIT 882.0m * (1 - 19.70%))
Current Ratio = 1.13 (Total Current Assets 3.45b / Total Current Liabilities 3.04b)
Debt / Equity = 0.62 (Debt 3.15b / totalStockholderEquity, last quarter 5.07b)
Debt / EBITDA = 1.96 (Net Debt 2.37b / EBITDA 1.21b)
Debt / FCF = 2.23 (Net Debt 2.37b / FCF TTM 1.06b)
Total Stockholder Equity = 4.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 605.0m / Total Assets 12.75b)
RoE = 12.28% (Net Income TTM 605.0m / Total Stockholder Equity 4.93b)
RoCE = 11.57% (EBIT 882.0m / Capital Employed (Equity 4.93b + L.T.Debt 2.70b))
RoIC = 9.14% (NOPAT 708.3m / Invested Capital 7.75b)
WACC = 7.01% (E(14.50b)/V(17.64b) * Re(8.39%) + D(3.15b)/V(17.64b) * Rd(0.83%) * (1-Tc(0.20)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 83.46% ; FCFF base≈748.8m ; Y1≈859.3m ; Y5≈1.20b
Fair Price DCF = 592.0 (EV 25.60b - Net Debt 2.37b = Equity 23.23b / Shares 39.2m; r=7.01% [WACC]; 5y FCF grow 17.29% → 2.90% )
EPS Correlation: 4.96 | EPS CAGR: 3.90% | SUE: 0.30 | # QB: 0
Revenue Correlation: 77.26 | Revenue CAGR: 8.32% | SUE: 2.18 | # QB: 3
EPS next Quarter (2026-03-31): EPS=3.87 | Chg30d=-0.042 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=17.64 | Chg30d=+0.085 | Revisions Net=+4 | Growth EPS=+14.6% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=20.54 | Chg30d=+0.190 | Revisions Net=+3 | Growth EPS=+16.4% | Growth Revenue=+3.6%
P/E Forward = 22.779
P/S = 1.2067
P/B = 3.2529
P/EG = 1.2881
Revenue TTM = 12.48b USD
EBIT TTM = 882.0m USD
EBITDA TTM = 1.21b USD
Long Term Debt = 2.70b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 3.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.37b USD (from netDebt column, last quarter)
Enterprise Value = 16.87b USD (14.50b + Debt 3.15b - CCE 774.0m)
Interest Coverage Ratio = 8.40 (Ebit TTM 882.0m / Interest Expense TTM 105.0m)
EV/FCF = 15.88x (Enterprise Value 16.87b / FCF TTM 1.06b)
FCF Yield = 6.30% (FCF TTM 1.06b / Enterprise Value 16.87b)
FCF Margin = 8.51% (FCF TTM 1.06b / Revenue TTM 12.48b)
Net Margin = 4.85% (Net Income TTM 605.0m / Revenue TTM 12.48b)
Gross Margin = 12.70% ((Revenue TTM 12.48b - Cost of Revenue TTM 10.90b) / Revenue TTM)
Gross Margin QoQ = 11.57% (prev 12.34%)
Tobins Q-Ratio = 1.32 (Enterprise Value 16.87b / Total Assets 12.75b)
Interest Expense / Debt = 0.83% (Interest Expense 26.0m / Debt 3.15b)
Taxrate = 19.70% (39.0m / 198.0m)
NOPAT = 708.3m (EBIT 882.0m * (1 - 19.70%))
Current Ratio = 1.13 (Total Current Assets 3.45b / Total Current Liabilities 3.04b)
Debt / Equity = 0.62 (Debt 3.15b / totalStockholderEquity, last quarter 5.07b)
Debt / EBITDA = 1.96 (Net Debt 2.37b / EBITDA 1.21b)
Debt / FCF = 2.23 (Net Debt 2.37b / FCF TTM 1.06b)
Total Stockholder Equity = 4.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 605.0m / Total Assets 12.75b)
RoE = 12.28% (Net Income TTM 605.0m / Total Stockholder Equity 4.93b)
RoCE = 11.57% (EBIT 882.0m / Capital Employed (Equity 4.93b + L.T.Debt 2.70b))
RoIC = 9.14% (NOPAT 708.3m / Invested Capital 7.75b)
WACC = 7.01% (E(14.50b)/V(17.64b) * Re(8.39%) + D(3.15b)/V(17.64b) * Rd(0.83%) * (1-Tc(0.20)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 83.46% ; FCFF base≈748.8m ; Y1≈859.3m ; Y5≈1.20b
Fair Price DCF = 592.0 (EV 25.60b - Net Debt 2.37b = Equity 23.23b / Shares 39.2m; r=7.01% [WACC]; 5y FCF grow 17.29% → 2.90% )
EPS Correlation: 4.96 | EPS CAGR: 3.90% | SUE: 0.30 | # QB: 0
Revenue Correlation: 77.26 | Revenue CAGR: 8.32% | SUE: 2.18 | # QB: 3
EPS next Quarter (2026-03-31): EPS=3.87 | Chg30d=-0.042 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=17.64 | Chg30d=+0.085 | Revisions Net=+4 | Growth EPS=+14.6% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=20.54 | Chg30d=+0.190 | Revisions Net=+3 | Growth EPS=+16.4% | Growth Revenue=+3.6%